Combination comprising N-acetyl-L-cysteine and its use
A combination of N-acetyl-L-cysteine, selenium in the form of selenomethionine and melatonin, and a medical product or pharmaceutical composition comprising such combination, useful for the treatment of a variety of diseases and conditions is described. The combination of N-acetyl-L-cysteine, selenium in the form of selenomethionine and melatonin is also useful for cosmetic treatment of skin and as an antibacterial agent.
1. A method of treating endometriosis, the method comprising:
administering to a patient in need thereof, a medical product consisting of one or more excipients and active agents consisting of:
(i) N-acetyl-L-cysteine;
(ii) selenium in the form of selenomethionine; and
(iii) melatonin;
and/or physiologically acceptable salts thereof.
2. The method of claim 1 , further comprising providing components (i)-(iii) as separate dosage units.
3. The method of claim 1 , wherein the N-acetyl-L-cysteine is present at a concentration of 3-10 wt. %, selenomethionine is present at a concentration of 0.3-1 wt. %, and melatonin is present at a concentration of 0.01-0.2 wt. % in the medical product.
4. The method of claim 3 , wherein N-acetyl-L-cysteine is present at a concentration of 5 wt. %, selenomethionine is present at a concentration of 0.5 wt. %, and melatonin is present at a concentration of 0.1 wt. % in the medical product.
5. The method of claim 1 , further comprising providing components (i)-(iii) as a single dosage unit.
6. The method of claim 1 , wherein components (i)-(iii) are administered simultaneously, sequentially, or by separate combinatorial administration.
7. The method of claim 1 , further comprising providing components (i)-(iii) as slow-release formulations.
8. The method of claim 1 , further comprising providing components (i)-(iii) in a form that is suitable for oral administration.
9. The method of claim 1 , further comprising providing components (i)-(iii) in a form suitable for rectal administration.
10. The method of claim 1 , further comprising providing components (i)-(iii) in a form suitable for intravenous or intraperitoneal administration.
11. The method of claim 1 , further comprising providing a kit comprising a set of dosage units, each dosage unit consisting of the one or more excipients and one or two of components (i)-(iii).
12. The method of claim 11 , wherein the dosage units are in a form suitable for oral administration.
13. The method of claim 1 , further comprising providing the medical product as a solid preparation.
14. The method of claim 13 , wherein the solid preparation comprises a tablet, a granule, a powder and/or a capsule.
15. The method of claim 1 , further comprising providing the medical product as a liquid preparation.
16. The method of claim 15 , wherein the liquid preparation comprises (a) a syrup, (b) a suspension, and/or (c) a dry powder to be reconstituted with a solvent.
17. A method of treating benign and malignant neoplasia, autoimmune diseases, neurodegenerative diseases, endocrinological diseases, type 2 diabetes, fibrosis, amyloidosis, polycystic ovary syndrome, dysmenorrhea, or bacterial infections in a mammal, the method comprising:
administering to a patient in need thereof, a combination consisting of one or more excipients and active agents consisting of:
(i) N-acetyl-L-cysteine;
(ii) selenium in the form of selenomethionine; and
(iii) melatonin
and/or physiologically acceptable salts thereof.
18. The method of claim 17 , wherein N-acetyl-L-cysteine is administered at a dose of 5-45 mg/kg/day, selenomethionine is administered at a dose of 0.4-1.2 μg/kg/day, and melatonin is administered at a dose of 0.02-0.08 mg/kg/day.
19. The method of claim 18 , wherein N-acetyl-L-cysteine is administered at a dose of 20-30 mg/kg/day, selenomethionine is administered at a dose of 0.8 μg/kg/day, and melatonin is administered at a dose of 0.04 mg/kg/day.
20. The method of claim 17 , wherein components (i)-(iii) are administered daily.